|
|
Article: U.S. FDA Clears Actiq for Breakthrough Cancer Pain; First Product Approved for Treating Breakthrough Cancer Pain.
- Article from:
- PR Newswire
- Article date:
- November 5, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SALT LAKE CITY, Nov. 5 /PRNewswire/ -- Anesta Corp. (Nasdaq: NSTA) announced today that the U.S. Food and Drug Administration (FDA) has cleared Actiq(R) (oral transmucosal fentanyl citrate) for marketing. Actiq is the first product specifically designed and studied for breakthrough cancer pain. It is indicated only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to opioid therapy. Breakthrough cancer pain is a flare of severe cancer pain, which "breaks through" the medication that is being administered at regular intervals for persistent cancer pain.
Breakthrough cancer pain is a ...